COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study of 1592U89 in Combination With Protease Inhibitors in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00002440
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Information provided by:
NIH AIDS Clinical Trials Information Service

Brief Summary:
The purpose of this study is to see if it is safe and effective to give 1592U89 plus certain protease inhibitors (PIs) to HIV-infected patients who never have been treated with anti-HIV drugs. This study also examines how the body processes these drugs when they are given together.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: Indinavir sulfate Drug: Ritonavir Drug: Abacavir sulfate Drug: Amprenavir Drug: Nelfinavir mesylate Drug: Saquinavir Phase 2

Detailed Description:
In this Phase II, open-label study patients (16 per treatment group) are randomized to receive 1592U89 in combination with one of five protease inhibitors: indinavir, saquinavir, ritonavir, nelfinavir, or 141W94 for up to 48 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 80 participants
Primary Purpose: Treatment
Official Title: An Open-Label, Phase II Trial to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of 1592U89 in Combination With Selected HIV-1 Protease Inhibitors in Antiretroviral-Naive, HIV-1-Infected Patients.

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Concurrent Medication:


  • Local treatment for Kaposi's sarcoma.
  • GM-CSF, G-CSF or erythropoietin.

Patients must have:

  • HIV-1 infection documented by a licensed HIV-1 antibody ELISA and confirmed by Western blot detection of HIV-1 antibody or a positive HIV-1 blood culture.
  • CD4+ cell count >= 100 cells/mm3 within 14 days of study drug administration.
  • HIV-1 RNA >= 5,000 copies/ml within 14 days of study drug administration.
  • No active or ongoing AIDS-defining opportunistic infection or disease.
  • Signed, informed consent from parent or legal guardian for patients less than 18 years of age.

Prior Medication:


Local treatment for Kaposi's sarcoma.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

  • Malabsorption syndrome, or other gastrointestinal dysfunction, that might interfere with drug absorption or render the patient unable to take oral medication.
  • Life-threatening infection or other serious medical condition that may compromise a patient's safety.

Concurrent Medication:


  • Other investigational agents. NOTE:
  • Those available through Treatment IND or expanded access programs are evaluated individually.
  • Chemotherapeutic agents for the initial 24 weeks of study (except local treatment for Kaposi's sarcoma).
  • Agents with documented anti-HIV activity in vitro.
  • Foscarnet.
  • Immunomodulating agents such as systemic corticosteroids, interleukins, thalidomide, anti-cytokine agents or interferons.
  • Antioxidants.

Concurrent Treatment:


Radiation therapy within the first 24 weeks of study.

Patients with the following prior conditions are excluded:

  • History of clinically relevant pancreatitis or hepatitis within the last 6 months.
  • Participation in an investigational HIV-1 vaccine trial.

Prior Medication:


  • Antiretroviral therapy, including reverse transcriptase inhibitor and protease inhibitor therapy.
  • Cytotoxic chemotherapeutic agents within 30 days of study drug administration.
  • HIV-1 vaccine dose within the 3 months prior to study drug administration.
  • Immunomodulating agents, such as systemic corticosteroids, interleukins or interferons within 30 days of study drug administration.

Prior Treatment:


Radiation therapy within 30 days of study drug administration. Alcohol or illicit drug use that may interfere with patient compliance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00002440

Layout table for location information
United States, California
UCSD Treatment Ctr
San Diego, California, United States, 921036329
United States, Connecticut
Yale U / New Haven Med Ctr / AIDS Clinical Trials Unit
New Haven, Connecticut, United States, 065102483
United States, Missouri
Kansas City AIDS Research Consortium
Kansas City, Missouri, United States, 64111
United States, New York
NYU Med Ctr / Dept of Medicine / AIDS Clinical Trial
New York, New York, United States, 10016
United States, North Carolina
Carolinas Med Ctr
Charlotte, North Carolina, United States, 28232
United States, Ohio
Case Western Reserve Univ / AIDS Clinical Trials Unit
Cleveland, Ohio, United States, 44106
United States, Pennsylvania
Univ of Pittsburgh Med Ctr
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Vanderbilt Univ Med Ctr
Nashville, Tennessee, United States, 372321302
Sponsors and Collaborators
Glaxo Wellcome
Layout table for additonal information Identifier: NCT00002440    
Other Study ID Numbers: 238J
First Posted: August 31, 2001    Key Record Dates
Last Update Posted: June 24, 2005
Last Verified: November 1998
Keywords provided by NIH AIDS Clinical Trials Information Service:
Drug Therapy, Combination
HIV Protease Inhibitors
HIV-1 Reverse Transcriptase
HIV Protease
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Antibiotics, Antitubercular
Antitubercular Agents
Anti-Bacterial Agents